



Prospera™
Transplant assessment

Renaisight™
Kidney gene panel

SYMPOSIA SERIES







Kidney Disease in the Genomic Era—Pediatrics Edition

Register at <https://www.natera.com/events/oh-symposias/>

Date & Time Friday, February 25 | 12:00 – 5:00 PM ET

Venue The Willard InterContinental | 1401 Pennsylvania Avenue NW, Washington, DC 20004
Livestream available

Chair Lisa M. Guay-Woodford, MD

11:45 – 1:00	Registration Open Onsite	
12:00 – 12:45	Lunch & Learn Renaisight: Expanding the scope of genetic testing in nephrology	 Trudy McKanna, MS CGC <i>Director, Medical Education, Natera</i>
1:00 – 1:10	Opening remarks	 Lisa M. Guay-Woodford, MD <i>McGehee Joyce Professor of Pediatrics Director, Center for Translational Research Director, Clinical and Translational Science Institute, Children's National</i>
1:10 – 1:35	The basics: Navigating a genetics report	 Hallie Andrew MS, CGC <i>Genetic Counselor, Children's National</i>
1:35 – 2:00	Practical application of genetic testing in pediatric nephrology	 Ashima Gulati, MD, PhD <i>Assistant Professor of Pediatrics (Nephrology), Children's National</i>
2:00 – 2:25	Cases and conundrums	Lisa M. Guay-Woodford, MD
2:25 – 2:50	Chronic kidney disease: New genetic insights	 Ali Gharavi, MD <i>Jay Meltzer Professor of Medicine Chief, Division of Nephrology, Columbia University</i>
2:50 – 3:15	After the Diagnosis: Approach to Rare Disorders	 Anthony Bleyer, MD <i>Professor of Medicine (Nephrology), Wake Forest University</i>
3:15 – 3:35	Break	
3:35 – 4:00	The exome is non-diagnostic: Now what?	 Seth Berger, MD, PhD <i>Assistant Professor of Pediatrics (Genetics) Children's National</i>
4:00 – 4:25	Impact of genetic testing: The parent's perspective	Parent Panel
4:25 – 4:50	Panel question & answer	All
4:50 – 5:00	Closing remarks	Lisa M. Guay-Woodford, MD
5:00 – 6:30	Reception with cocktails and hors d'oeuvres	

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com

The test described has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). Although FDA is exercising enforcement discretion of premarket review and other regulations for laboratory-developed tests in the US, certification of the laboratory is required under CLIA to ensure the quality and validity of the tests. CAP accredited, ISO 13485 certified, and CLIA certified. © 2021 Natera, Inc. All Rights Reserved. OH_Symp_flyer1_20210104_NAT-8020826

